EE04991B1 - Osake, ravimvorm, nende valmistamismeetodid, osakeste kasutamine ning farmatseutiline pakend - Google Patents

Osake, ravimvorm, nende valmistamismeetodid, osakeste kasutamine ning farmatseutiline pakend

Info

Publication number
EE04991B1
EE04991B1 EEP200200151A EEP200200151A EE04991B1 EE 04991 B1 EE04991 B1 EE 04991B1 EE P200200151 A EEP200200151 A EE P200200151A EE P200200151 A EEP200200151 A EE P200200151A EE 04991 B1 EE04991 B1 EE 04991B1
Authority
EE
Estonia
Prior art keywords
pharmaceutical
particle
particles
preparation
methods
Prior art date
Application number
EEP200200151A
Other languages
English (en)
Estonian (et)
Inventor
Verreck Geert
Elvire Colette Baert Lieven
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of EE200200151A publication Critical patent/EE200200151A/xx
Publication of EE04991B1 publication Critical patent/EE04991B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
EEP200200151A 1999-09-24 2000-08-31 Osake, ravimvorm, nende valmistamismeetodid, osakeste kasutamine ning farmatseutiline pakend EE04991B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99203128 1999-09-24
PCT/EP2000/008522 WO2001022938A1 (en) 1999-09-24 2000-08-31 Antiviral compositions

Publications (2)

Publication Number Publication Date
EE200200151A EE200200151A (et) 2003-04-15
EE04991B1 true EE04991B1 (et) 2008-04-15

Family

ID=8240674

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200151A EE04991B1 (et) 1999-09-24 2000-08-31 Osake, ravimvorm, nende valmistamismeetodid, osakeste kasutamine ning farmatseutiline pakend

Country Status (35)

Country Link
US (4) US7241458B1 (hr)
EP (1) EP1225874B1 (hr)
JP (1) JP4919566B2 (hr)
KR (2) KR100820605B1 (hr)
CN (1) CN1234347C (hr)
AP (1) AP1639A (hr)
AT (1) ATE316781T1 (hr)
AU (2) AU775360B2 (hr)
BG (1) BG65754B1 (hr)
BR (1) BRPI0014271B1 (hr)
CA (1) CA2384188C (hr)
CY (1) CY1105268T1 (hr)
CZ (1) CZ300712B6 (hr)
DE (1) DE60025837T2 (hr)
DK (1) DK1225874T3 (hr)
EA (1) EA005423B1 (hr)
EE (1) EE04991B1 (hr)
ES (1) ES2258018T3 (hr)
HK (1) HK1048768B (hr)
HR (1) HRP20020247B1 (hr)
HU (1) HU228449B1 (hr)
IL (1) IL148801A0 (hr)
IS (1) IS2567B (hr)
MX (1) MXPA02003182A (hr)
NO (1) NO333358B1 (hr)
NZ (1) NZ517025A (hr)
OA (1) OA12029A (hr)
PL (1) PL207590B1 (hr)
PT (1) PT1225874E (hr)
SI (1) SI1225874T1 (hr)
SK (1) SK285240B6 (hr)
TR (1) TR200200763T2 (hr)
UA (1) UA74797C2 (hr)
WO (1) WO2001022938A1 (hr)
ZA (1) ZA200202289B (hr)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2386218A1 (en) 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
WO2001034119A2 (en) 1999-11-12 2001-05-17 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
MXPA02007957A (es) 2000-02-17 2002-11-29 Amgen Inc Inhibidores de cinasas.
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
IL157608A0 (en) 2001-02-27 2004-03-28 Teva Pharma New crystal forms of lamotrigine and processes for their preparations
WO2003000235A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
ES2314106T3 (es) 2001-10-17 2009-03-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Derivados de pirimidina, agentes farmaceuticos que contiene dichos compuestos, uso y metodo para su obtencion.
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ATE511858T1 (de) 2002-02-05 2011-06-15 Astellas Pharma Inc 2,4,6-triamino-1,3,5-triazin-derivat
ATE357217T1 (de) * 2002-04-23 2007-04-15 Teva Pharma Pharmazeutische zusammensetzung enthaltend lamotrigine-partikel mit definierter morphologie
AR039540A1 (es) 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
CN1678321A (zh) 2002-07-29 2005-10-05 里格尔药品股份有限公司 用2,4－嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法
KR101140785B1 (ko) 2002-08-09 2012-05-03 얀센 파마슈티카 엔.브이. 4-〔〔4-〔〔4-（2-시아노에테닐）-2,6-디메틸페닐〕아미노〕-2-피리미디닐〕아미노〕벤조니트릴의 제조방법
US7815934B2 (en) 2002-09-20 2010-10-19 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
PL377795A1 (pl) * 2002-11-28 2006-02-20 Schering Aktiengesellschaft Pirymidyny będące inhibitorami Chk, Pdk i Akt, sposób ich wytwarzania oraz ich zastosowanie jako środków farmaceutycznych
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
DK1599468T3 (da) 2003-01-14 2008-02-04 Arena Pharm Inc 1,2,3-trisubstituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser forbundet dermed såsom diabetes og hyperglykæmi
MXPA05008364A (es) * 2003-02-07 2005-11-04 Janssen Pharmaceutica Nv Derivados de pirimidina para la prevencion de una infeccion por vih.
CL2004000306A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa.
CN1822843B (zh) 2003-07-17 2010-04-28 泰博特克药品有限公司 制备含有抗病毒药物颗粒的方法
CN1849318B (zh) 2003-07-30 2011-10-12 里格尔药品股份有限公司 用2,4-嘧啶二胺化合物预防和治疗自体免疫疾病的方法
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
EP1678169B1 (en) 2003-10-17 2009-07-22 Astrazeneca AB 4-(pyrazol-3-ylamino)pyrimidine derivatives for use in the treatment of cancer
PL1725540T3 (pl) 2004-03-05 2013-02-28 Hoffmann La Roche Diaminopirymidyny jako antagoniści p2x3 i p2x2/3
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
US7767677B2 (en) 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
AR051026A1 (es) 2004-09-20 2006-12-13 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
JP4958785B2 (ja) 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体およびステアロイル−ＣｏＡデサチュラーゼインヒビターとしてのそれらの使用
WO2006034279A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
TW200624427A (en) 2004-09-20 2006-07-16 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
SI1814878T1 (sl) 2004-11-24 2012-06-29 Rigel Pharmaceuticals Inc Spojine spiro-2,4-pirimidindiamina in njihova uporaba
PT1856135E (pt) 2005-01-19 2010-02-26 Rigel Pharmaceuticals Inc Pró-fármacos de compostos 2,4-pirimidinodiamina e suas utilizações
MX2007009843A (es) 2005-02-16 2007-08-23 Astrazeneca Ab Compuestos quimicos.
US7935711B2 (en) * 2005-02-18 2011-05-03 Tibotec Pharmaceuticals Ltd. HIV inhibiting 2-(4-cyanophenylamino) pyrimidine oxide derivatives
US20080214588A1 (en) * 2005-03-04 2008-09-04 Herman Augustinus De Kock Hiv Inhibiting 2-(4-Cyanophenyl)-6-Hydroxylaminopyrimidines
AR056652A1 (es) 2005-04-11 2007-10-17 Tibotec Pharm Ltd Derivados de (1,10-b dihidro-2-(aminoalquil-fenil) -5h-pirazolo (1,5-c) (1,3)benzoxazin-5-il) fenilmetanona y su uso en la fabricacion de un medicamento
JP2008540622A (ja) 2005-05-16 2008-11-20 アストラゼネカ アクチボラグ 化合物
PT1888537E (pt) 2005-05-26 2013-11-26 Janssen R & D Ireland Processo para preparar 4-[(1,6-dihidro-6-oxo-2-pirimidinil)amino benzonitrilo
US8541457B2 (en) 2005-06-03 2013-09-24 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
JP4850913B2 (ja) 2005-09-01 2012-01-11 エフ．ホフマン−ラ ロシュ アーゲー Ｐ２ｘ３及びｐ２ｘ２／３調節因子としてのジアミノピリジン
ES2601178T3 (es) 2005-09-01 2017-02-14 F. Hoffmann-La Roche Ag Diaminopirimidinas como moduladores de P2X3 y P3X2/3
WO2007025899A1 (en) 2005-09-01 2007-03-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
DK1945631T3 (da) 2005-10-28 2012-10-22 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer
EP1942872A2 (en) * 2005-11-04 2008-07-16 Eastman Chemical Company Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
RS52053B (en) * 2006-06-06 2012-04-30 Tibotec Pharmaceuticals PROCESS FOR PREPARATION OF SPRAY DRY FORMULATIONS TMC125
EP2526932B1 (en) 2006-06-19 2017-06-07 Alpharma Pharmaceuticals LLC Pharmaceutical composition
EP2073797A2 (en) * 2006-10-11 2009-07-01 Alpharma, Inc. Pharmaceutical compositions
EP2104491B1 (en) 2006-12-06 2017-02-22 Janssen Sciences Ireland UC Hydrobromide salt of an anti-hiv compound
AR065720A1 (es) * 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
HUE028598T2 (en) * 2007-06-08 2016-12-28 Boehringer Ingelheim Int Extended release nevirapine preparation
RU2010102067A (ru) * 2007-06-25 2011-07-27 Тиботек Фармасьютикалз (Ie) Комбинированные композиции, включающие дарунавир и этравирин
US8410124B2 (en) 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
US7989465B2 (en) * 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
TWI475996B (zh) * 2007-10-19 2015-03-11 Celgene Avilomics Res Inc 雜芳基化合物及其用途
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP2224805A4 (en) * 2007-12-17 2013-10-16 Alpharma Pharmaceuticals Llc PHARMACEUTICAL COMPOSITION
EP2326626B1 (en) * 2008-08-20 2013-10-16 Merck Sharp & Dohme Corp. Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
EP2331511A1 (en) * 2008-08-20 2011-06-15 Schering Corporation Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
JP2012502906A (ja) * 2008-09-17 2012-02-02 ネクター セラピューティックス オリゴマー−プロテアーゼ阻害剤コンジュゲート
CN101744823B (zh) * 2008-12-17 2013-06-19 广东东阳光药业有限公司 一种二氢嘧啶类化合物的固体分散体及其药用制剂
US8754093B2 (en) 2009-03-30 2014-06-17 Janssen R&D Ireland Co-crystal of etravirine and nicotinamide
JP2012529512A (ja) * 2009-06-08 2012-11-22 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー トリアジン誘導体類及びそれらの治療応用
RU2556986C2 (ru) * 2009-06-22 2015-07-20 Эмкьюар Фармасьютикалз Лимитед Способ синтеза диарилпиримидинового ненуклеозидного ингибитора обратной транскриптазы
PL2576541T3 (pl) 2010-06-04 2016-10-31 Pochodne aminopirymidyny jako modulatory lrrk2
US10894787B2 (en) 2010-09-22 2021-01-19 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
LT3124483T (lt) 2010-11-10 2019-09-25 Genentech, Inc. Pirazolo aminopirimidino dariniai, kaip lrrk2 moduliatoriai
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
CN104363921B (zh) * 2012-04-11 2016-05-18 陶氏环球技术有限责任公司 新型缓释剂型
WO2013154981A1 (en) * 2012-04-11 2013-10-17 Dow Global Technologies Llc Melt-extruded composition comprising a cellulose ether
JP6185559B2 (ja) * 2012-04-11 2017-08-23 ダウ グローバル テクノロジーズ エルエルシー 有機希釈剤およびセルロースエーテルを含む組成物
PL3176170T3 (pl) 2012-06-13 2019-05-31 Incyte Holdings Corp Podstawione związki tricykliczne jako inhibitory fgfr
WO2014009968A2 (en) * 2012-07-12 2014-01-16 Hetero Research Foundation Process for rilpivirine using novel intermediate
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
PT2986610T (pt) 2013-04-19 2018-03-09 Incyte Holdings Corp Heterociclos bicíclicos como inibidores de fgfr
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016112075A1 (en) 2015-01-06 2016-07-14 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
ES2751669T3 (es) 2015-02-20 2020-04-01 Incyte Corp Heterociclos bicíclicos como inhibidores FGFR
AR100459A1 (es) * 2015-05-15 2016-10-05 Química Luar S R L Una composición farmacéutica antiviral de uso tópico
SI3310760T1 (sl) 2015-06-22 2023-02-28 Arena Pharmaceuticals, Inc. Kristalinična L-argininska sol (R)-2-(7-(4-ciklopentil-3-(trifluorometil)benziloksi)-1,2,3,4- tetrahidrociklo-penta(b)indol-3-il)ocetne kisline za uporabo pri motnjah, povezanih z receptorjem S1P1
CA3053418A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
US10172856B2 (en) 2017-04-06 2019-01-08 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives as histamine H4 modulators
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
KR20210018264A (ko) 2018-05-04 2021-02-17 인사이트 코포레이션 Fgfr 억제제의 염
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
PE20221085A1 (es) 2019-10-14 2022-07-05 Incyte Corp Heterociclos biciclicos como inhibidores de fgfr
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
AU2020391004A1 (en) 2019-11-29 2022-04-07 Aptorum Therapeutics Limited Composition including rilpivirine and use thereof for treating tumors or cancer
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
KR102145925B1 (ko) 2020-03-03 2020-08-19 협동조합 바이오융합기술 사포닌 성분이 함유된 항 바이러스용 조성물의 제조방법
CN111875548A (zh) * 2020-07-16 2020-11-03 山东大学 一种5位芳环取代的二芳基嘧啶类衍生物及其制备方法与应用
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2742466A (en) 1956-04-17 Chx n nhx c c
US230963A (en) 1880-08-10 John kobeetson
US2671810A (en) 1952-05-24 1954-03-09 Du Pont Long-chain diketones
US2748124A (en) 1954-05-06 1956-05-29 Searle & Co 1-(4-anilino-2-pyrimidino)-3-alkylureas
SU143808A1 (ru) 1961-02-14 1961-11-30 Н.В. Козлова Способ получени 2-хлор-4,6-ди и 2,4,6-три-(2,4-дихлоранилин)-симм. триазинов
GB1010998A (en) 1962-10-09 1965-11-24 British Petroleum Co Pyrimidine derivatives
US3478030A (en) 1966-06-27 1969-11-11 Abbott Lab Benzamide substituted anilino aminopyrimidines
BE754242A (fr) 1970-07-15 1971-02-01 Geigy Ag J R Diamino-s-triazines et dinitro-s-triazines
DE2038182C3 (de) 1970-07-31 1980-10-09 Ciba-Geigy Ag, Basel (Schweiz) 2-Substituierte 4,6-Diamino-stri azine
GB1483271A (en) 1975-03-22 1977-08-17 Ciba Geigy Ag Pigment complexes
GB1477349A (en) 1975-09-24 1977-06-22 Ciba Geigy Ag Azo pigments
US4096206A (en) 1976-02-09 1978-06-20 Borg-Warner Corporation Flame-retardant triazines
FR2400535A1 (fr) 1977-01-27 1979-03-16 Borg Warner Composition de polymere contenant des tris(haloarylamino)triazines ou des tris(haloarylthio)triazines fournissant une aptitude au retardement d'inflammation
FR2398740A1 (fr) 1978-11-06 1979-02-23 Borg Warner Compose fournissant une aptitude au retardement d'inflammation dans un polymere
JPS57203072A (en) 1981-06-05 1982-12-13 Sankyo Co Ltd 4-anilinopyrimidine derivative, its preparation, antidepressant comprising it as active ingredient
US4659363A (en) 1983-07-25 1987-04-21 Ciba-Geigy Corporation N-(2-nitrophenyl)-2-aminopyrimidine derivatives, the preparation and use thereof
US4652645A (en) 1983-11-16 1987-03-24 Ciba-Geigy Corporation Cationic compounds
ATE60591T1 (de) 1984-06-25 1991-02-15 Ciba Geigy Ag Pyrimidinderivate wirksam als schaedlingsbekaempfungsmittel.
JPH0784445B2 (ja) * 1986-12-03 1995-09-13 クミアイ化学工業株式会社 ピリミジン誘導体および農園芸用殺菌剤
KR950006713B1 (ko) 1988-03-31 1995-06-21 미쓰비시 가세이 가부시끼가이샤 6-치환 비환식 피리미딘뉴클레오시드 유도체 및 그 유도체를 유효성분으로 하는 항 비루스제
JPH0252360A (ja) 1988-08-15 1990-02-21 Fujitsu Ltd 電子写真感光体
US4980371A (en) 1988-12-21 1990-12-25 Merrell Dow Pharmaceuticals Antiretroviral furan ketones
TR25912A (tr) 1989-03-22 1993-11-01 Ciba Geigy Ag 2-ANILIN-PRIMIDIN TüREVLERI BU MADDELERINELDE EDIL MELERI VE ZARARLILARA KARSI MüCADELEDE KULLANILMA- LARI
IE63502B1 (en) 1989-04-21 1995-05-03 Zeneca Ltd Aminopyrimidine derivatives useful for treating cardiovascular disorders
JPH02300264A (ja) 1989-05-16 1990-12-12 Fuji Photo Film Co Ltd アミノピリミジンアゾメチン色素とその製造方法
JPH02308248A (ja) 1989-05-24 1990-12-21 Fuji Photo Film Co Ltd アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料
US5064963A (en) 1990-04-25 1991-11-12 American Cyanamid Company Process for the synthesis of n-(3-(1h-imidazol-1-yl)phenyl-4-(substituted)-2-pyrimidinamines
GB9012592D0 (en) 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
IE75693B1 (en) 1990-07-10 1997-09-10 Janssen Pharmaceutica Nv HIV-inhibiting benzeneacetamide derivatives
JPH04159381A (ja) 1990-10-23 1992-06-02 Arakawa Chem Ind Co Ltd ロジンエステルの製造方法
EP0541966A3 (en) 1991-11-15 1994-09-07 American Cyanamid Co Process for preparing amide derivatives from halomines and acid halides
US5283274A (en) 1992-06-19 1994-02-01 Uniroyal Chemical Company, Inc. Substituted pyrimidines and substituted triazines as rubber-to-metal adhesion promoters
IL106324A (en) 1992-07-17 1998-09-24 Shell Int Research Transformed pyrimidine compounds, their preparation and use as pesticides
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
SG49651A1 (en) 1993-02-22 1998-06-15 Janssen Pharmaceutica Nv Method of reversing resistance of hiv-1 strains to zidovudine
WO1995010506A1 (en) * 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
CZ101496A3 (en) 1993-10-12 1996-11-13 Du Pont Merck Pharma N-alkyl-n-aryl-pyrimidinamines and derivatives thereof
GB9325217D0 (en) 1993-12-09 1994-02-09 Zeneca Ltd Pyrimidine derivatives
DE19509807A1 (de) * 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
TW530047B (en) 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
IL114208A0 (en) 1994-06-27 1995-10-31 Merck & Co Inc Combinations of compounds pharmaceutical compositions containing them and their use as hiv protease inhibitors
TW401303B (en) 1994-07-01 2000-08-11 Janssen Pharmaceutica Nv Anti-HIV triple combination
US5574040A (en) 1995-01-06 1996-11-12 Picower Institute For Medical Research Pyrimidine compounds and methods of use to derivatize neighboring lysine residues in proteins under physiologic conditions
JP3691101B2 (ja) 1995-01-24 2005-08-31 三洋電機株式会社 有機エレクトロルミネッセンス素子
DE19504832A1 (de) * 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
US5691364A (en) 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
US5837436A (en) 1995-07-28 1998-11-17 Fuji Photo Film Co., Ltd. Silver halide color photographic material and package thereof
JPH09101590A (ja) 1995-07-28 1997-04-15 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料およびその包装体
JPH0968784A (ja) 1995-08-31 1997-03-11 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
JPH0980676A (ja) 1995-09-13 1997-03-28 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料およびその包装体
GB9519197D0 (en) 1995-09-20 1995-11-22 Affinity Chromatography Ltd Novel affinity ligands and their use
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
CN1163401A (zh) 1996-02-13 1997-10-29 李占元 全自动血球计数仪试剂及配制方法
GB9619284D0 (en) 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
EP0872233A1 (en) 1997-04-14 1998-10-21 Janssen Pharmaceutica N.V. Antiretroviral compositions with improved bioavailability
JPH11116555A (ja) 1997-10-14 1999-04-27 Ube Ind Ltd ４−アニリノピリミジン誘導体及びそれを有効成分とする農園芸用の殺虫・殺ダニ・殺菌剤
ATE245641T1 (de) 1998-02-17 2003-08-15 Tularik Inc Antivirale pyrimidinderivate
BRPI9909191B8 (pt) * 1998-03-27 2021-07-06 Janssen Pharmaceutica Nv derivados de pirimidina inibidores do hiv, seu uso e composição farmacêutica que os compreende
EP0945442A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted pyrimidine derivatives
EP0945447A1 (en) * 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
ES2193660T3 (es) 1998-03-27 2003-11-01 Janssen Pharmaceutica Nv Derivados de pirimidina inhibidores de vih.
JP2000111191A (ja) 1998-08-04 2000-04-18 Tokyo Gas Co Ltd 吸収冷温水機
SK287269B6 (sk) 1998-11-10 2010-05-07 Janssen Pharmaceutica N. V. Derivát pyrimidínu, jeho použitie, spôsob jeho prípravy a farmaceutická kompozícia, kombinácia a produkt s jeho obsahom
US6876717B1 (en) * 2004-08-19 2005-04-05 Intel Corporation Multi-stage programmable Johnson counter

Also Published As

Publication number Publication date
EP1225874B1 (en) 2006-02-01
DK1225874T3 (da) 2006-06-12
BRPI0014271B1 (pt) 2021-06-22
HK1048768B (zh) 2006-08-04
ATE316781T1 (de) 2006-02-15
CY1105268T1 (el) 2010-03-03
OA12029A (en) 2006-04-28
CZ2002907A3 (cs) 2002-05-15
NO20021443L (no) 2002-03-22
PL207590B1 (pl) 2011-01-31
MXPA02003182A (es) 2002-09-30
US7887845B2 (en) 2011-02-15
UA74797C2 (uk) 2006-02-15
AP1639A (en) 2006-07-24
SK3762002A3 (en) 2002-09-10
EE200200151A (et) 2003-04-15
AP2002002482A0 (en) 2002-06-30
EA005423B1 (ru) 2005-02-24
IS6256A (is) 2002-01-31
AU2004224973B2 (en) 2005-08-25
IS2567B (is) 2009-12-15
NO333358B1 (no) 2013-05-13
CN1234347C (zh) 2006-01-04
US20100172970A1 (en) 2010-07-08
DE60025837T2 (de) 2006-11-02
HUP0203568A3 (en) 2006-07-28
US7241458B1 (en) 2007-07-10
HK1048768A1 (en) 2003-04-17
JP4919566B2 (ja) 2012-04-18
ZA200202289B (en) 2003-08-27
KR100785360B1 (ko) 2007-12-18
EP1225874A1 (en) 2002-07-31
CA2384188A1 (en) 2001-04-05
PT1225874E (pt) 2006-06-30
BR0014271A (pt) 2002-05-21
KR20070036805A (ko) 2007-04-03
PL354026A1 (en) 2003-12-15
SI1225874T1 (sl) 2006-06-30
DE60025837D1 (de) 2006-04-13
HRP20020247A2 (en) 2004-04-30
EA200200401A1 (ru) 2002-10-31
HRP20020247B1 (hr) 2011-02-28
KR20020063847A (ko) 2002-08-05
SK285240B6 (sk) 2006-09-07
NZ517025A (en) 2003-07-25
HUP0203568A2 (hu) 2003-02-28
KR100820605B1 (ko) 2008-04-08
TR200200763T2 (tr) 2003-09-22
HU228449B1 (en) 2013-03-28
CA2384188C (en) 2008-06-17
AU7512700A (en) 2001-04-30
US20070196478A1 (en) 2007-08-23
IL148801A0 (en) 2002-09-12
CN1376057A (zh) 2002-10-23
WO2001022938A1 (en) 2001-04-05
JP2003510264A (ja) 2003-03-18
BG106521A (bg) 2002-12-29
NO20021443D0 (no) 2002-03-22
AU2004224973A1 (en) 2004-11-25
CZ300712B6 (cs) 2009-07-22
AU2004224973C1 (en) 2006-06-01
ES2258018T3 (es) 2006-08-16
AU775360B2 (en) 2004-07-29
US20060127487A1 (en) 2006-06-15
BG65754B1 (bg) 2009-10-30

Similar Documents

Publication Publication Date Title
EE200200151A (et) Osake, ravimvorm, nende valmistamismeetodid, osakeste kasutamine ning farmatseutiline pakend
EE9800304A (et) Osakesed, nende valmistamismeetod ja kasutamine, farmatseutiline doseerimisvorm ja selle valmistamismeetod, tahke dispersioon ning farmatseutiline pakend
AU5936400A (en) Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
HUP0300593A3 (en) Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets
HUP0301046A3 (en) Quinazoline derivatives for the treatment of tumours, process for their preparation and pharmaceutical compositions containing them
EE200100319A (et) Reguleeritud vabanemisega galantamiinipreparaat, meetod selle valmistamiseks, seda sisaldav doseerimisvorm ning farmatseutiline pakend
NO20014835L (no) Fremgangsmate for fremstilling av monodisperse polymerpartikler
HUP0200309A2 (en) Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression, process for their preparation and pharmaceutical compositions containing them
EE9800383A (et) Meetod bioloogiliselt sobivate biodegradeeruvate mikroosakeste valmistamiseks, mikroosakesed ja nendest koosnev materjal, farmatseutiline kompositsioon ning mikroosakeste kasutamine
IL150539A0 (en) Novel 1,3-dihydro-2h-indol-2-one derivatives, preparation method and pharmaceutical compositions containing them
EP1242112A4 (en) PRODUCTS CONTAINING MEDICINANT SUBSTANCE PARTICLES AND PROCESS FOR PREPARING THE SAME
HUP0104687A3 (en) Methods for preparing coated drug particles and pharmaceutical formulations thereof
PL361833A1 (en) Modified inorganic particles, method of their manufakturing and use thereof
IL162185A0 (en) Phenylpropionate derivatives, methods for the preparation thereof and pharmaceutical compositions containing the same
PL377931A1 (pl) Farmaceutyczne preparaty donosowe oraz sposoby ich stosowania
AU1080901A (en) Catalyst compositions employing sol particles and methods of using the same
HUP0202781A3 (en) Betha-carboline particulate form, pharmaceutical compositions containing it, their preparations and their use
FR2807038B1 (fr) Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant
FR2811992B1 (fr) Melanges de polysaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant
IL158297A0 (en) Pharmaceutical compositions containing immune globulin and methods for the preparation thereof
IL151912A0 (en) Pyrolidine derivatives, their preparation and pharmaceutical compositions containing them
IL159006A0 (en) Phenoxy-phenyl derivatives and pharmaceutical compositions containing the same
EP1476174A4 (en) PHARMACEUTICAL PREPARATION WITH PROPHYLACTIC EFFECTS ON LAMIVUDINE-RELATED REACTIONS AND PHARMACORESISTANCE, AND METHODS OF USING THE SAME
IL156532A0 (en) Lipid microparticles, their preparation and pharmaceutical compositions containing them
FR2857971B1 (fr) Melanges d'oligosaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231